KROS 205
Alternative Names: ENV-205; KROS-205Latest Information Update: 16 Mar 2022
At a glance
- Originator Cedars-Sinai Medical Center
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Feb 2022 Kairos Pharma has patent protection for KROS 205 (Kairos Pharma website, February 2022)
- 23 Feb 2022 Early research in Solid tumours in USA (unspecified route), prior to February 2022 (Kairos Pharma pipeline, February 2022)
- 23 Feb 2022 Preclinical trials in Solid tumours in USA (unspecified route), prior to February 2022 (Kairos Pharma pipeline, February 2022)